- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Manufacturers and the Cost of Biosimilars and Biologics
Amanda Forys, MSPH: So what if a manufacturer was sitting here and they said, “But hey Christy, I am providing "the As;" I’m giving the patient accessibility, so they might not want to be on the biosimilar because they might not think it’s effective, or they want to be on the biosimilar but still the biosimilar and the biologic originator were both very expensive, [and] neither one is on their formulary. I’m a program offering the patient that assistance,” what do you say to that manufacturer?
Christy M. Gamble, JD, DrPH, MPH: Well, that’s an interesting argument. I would definitely still say that we have to have a conversation about cost here. We have to make sure that we’re putting the patient first. We have to also make sure that we’re not bankrupting taxpayers while we’re trying to get patients these drugs. We want to make sure that patients get the most effective drug, but we also want to make sure that costs are controlled. That’s a discussion that we should be having versus whether or not this patient assistance program should be in existence or not. It’s in existence because of the sky-rocketing price of these drugs.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
